Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Receivables - Net: 2020-2025

Historic Receivables - Net for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $53.8 million.

  • Xeris Biopharma Holdings' Receivables - Net rose 30.66% to $53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.8 million, marking a year-over-year increase of 30.66%. This contributed to the annual value of $40.4 million for FY2024, which is 3.11% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Receivables - Net is $53.8 million, which was up 1.33% from $53.0 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Receivables - Net registered a high of $53.8 million during Q3 2025, and its lowest value of $13.6 million during Q3 2021.
  • Its 3-year average for Receivables - Net is $41.9 million, with a median of $41.1 million in 2024.
  • In the last 5 years, Xeris Biopharma Holdings' Receivables - Net spiked by 153.91% in 2021 and then fell by 10.50% in 2024.
  • Xeris Biopharma Holdings' Receivables - Net (Quarterly) stood at $17.5 million in 2021, then soared by 76.62% to $30.8 million in 2022, then climbed by 27.14% to $39.2 million in 2023, then increased by 3.11% to $40.4 million in 2024, then soared by 30.66% to $53.8 million in 2025.
  • Its Receivables - Net was $53.8 million in Q3 2025, compared to $53.0 million in Q2 2025 and $46.3 million in Q1 2025.